High grade malignant peripheral nerve sheath tumors: Outcome of 62 patients with localized disease and review of the literature

Journal of Chemotherapy

Volumn 22, Issue 6, 2010, Pages 413-418

  Longhi, A ^a   Errani, C ^a   Magagnoli, G ^b   Alberghini, M ^b   Gambarotti, M ^b   Mercuri, M ^b   Ferrari, S ^a  

^a Chemotherapy   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Adjuvant treatment; Chemotherapy; MPNST; Schwannoma; Soft tissue sarcoma

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; MIDDLE AGED; NERVE SHEATH TUMOR; PATHOLOGY; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958253870     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.6.413     Document Type: Article

References (36)

1. d Ed., St Louis, MO; Mosby. 1995: 889-928.
2. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97:340-9.
3. Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors in children. Am J Surg Pathol 1992;16:694-707.
4. Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnson S. Molecular and cytogenetic analysis of tumors in Von Recklinghausen's neurofibromatosis. Genes Chromosomes Cancer 1991; 3:62-70.
5. Doom PF, Molenaar WM, Buter J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol, 1995; 21:78-82.
6. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62: 1573-7.
7. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral sheath tumours. A clinicopathological study of 120 cases. Cancer 1986;57(10):2006-21.
8. McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Wester Beek R, et al. A clinical study of type 1 neurofibromatosis in northwest England. J Med Genet 1999;36:197-203.
9. Foley KM, Woodroff JM, Ellis FT, Posner JB. Radiation-induced malignant and atypical peripheral nerve sheath tumours. Ann Neurol 1980;51:311-18.
10. D'Agostino AN, Soule EH, Miller RH. Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (Von Recklinghausen's disease). Cancer 1963;16:1003-14.
11. Fletcher CDM. Current Topics in Pathology, Berlin: Springer Verlag. 1995; 89:333-354.
12. Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factor affecting survival. J Clin Oncol 1987;5(4):601-12.
13. Koea JB, Leung D, Lewis JJ, Brennan MF. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 2003;10(4):432-40.
14. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL, Malignant peripheral nerve sheath tumour: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998:42:351-360.
15. ESordillo PP, Helson L, Hajdu SI, Magill GB, Kosloff C, Golbey RB, et al. Malignant schwannoma-clinical characteristics, survival and response to therapy. Cancer 1981; 47:2503-9.
16. Anghileri M, Miceli R, Rore M, Mariani L, Ferrari A, Mussi C, et al, Malignant peripheral sheath tumours, prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006;107:1065-74.
17. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al, Pediatric malignant peripheral nerve sheath tumor. The Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005;23:8422-8430.
18. Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977;40:1562-70.
19. Enneking WF, Spanier SS, Goodman MA. A system for surgical staging of musculoskeletal sarcoma. Clin Orthoped Related Res 1980;153:106-120.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791-6.
22. Koea JB. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 2003;10(4): 432-40.
23. Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke M, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. Ann Oncol. 2010; July 23 (Epub).
24. Steins MB, Serve H, ZUhlsdorf M. Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy. Oncol Rep. 2002;9(3):627-630
25. Kinebuchi Y, Noguchi W, Igawa Y, Nishizawa O. Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol. 2005;10(5):353-6.
26. Johansson G, Manlier YY, Collins MH. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumours. Mol Cancer Ther 2008;7(5):1237-45.
27. Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther 2008;7(6):810-813.
28. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Unde-via SD. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27(19):3133-40.
29. Holtkamp N, Malzer E, Zietsch J EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol. 2008;10(6):946-57.
30. Albritton KH, Rankin C, Cofffin CM, Ratner N, Budd GT, Schuetze SM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol, 2006; 24, 18S: 9518.
31. Wojtkowiak JW, Fouad F, La Londe DT. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 2008;326(1):1-11
32. Roth TM, Ramamurthy P, Muir D, Wallace MR, Zhu Y, Chang L, et al. Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin. Dev Dyn 2008;237(2):513-24.
33. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-cd44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009;69(12):4992-8.
34. Demestre M, Messerli SM, Celli N, Shahhossini M, Kluwe L, Mautner V, et al. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res. 2009;23(2):226-30.
35. Messerli SM, Ahn MR, Kunimasa K. Artepillin C (ARC) in Brazilian green propolis selectively blocks oncogenic PAK1 signaling and suppresses the growth of NF tumors in mice. Phytother Res. 2009;23(3):423-7.
36. Pisters PW. Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out? J Clin Oncol 2006; 24(4): 549-551.